Abstract
Venous thrombosis is a common medical disorder affecting nearly one million Americans each year. This review will focus primarily on the formation of venous thrombosis as well as current and future treatment options. While the full pathophysiology of venous thrombosis is not known, recent evidence points to a role for von Willebrand Factor, platelets, and neutrophils in thrombus formation. Many laboratory and imaging tests may be used for the diagnosis of venous thrombosis (VTE), but risk factor identification and clinical examination should not be overlooked as they are vital in assuring accurate treatment and patient identification. Historically heparin followed by a vitamin K antagonist has been the standard of care for treatment of VTE, but increasing data involving factor Xa inhibitors and direct thrombin inhibitors may mean a shift in first-line therapy in the very near future. Invasive therapies such as catheter-directed thrombolysis have also shown promise in the treatment of venous thrombosis and will likely see increased use in the future.
Keywords: Venous thrombolism, pulmonary embolism, heparin, warfarin, EKOS, factor Xa inhibitors, direct thrombin inhibitors.
Current Drug Targets
Title:Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
Volume: 15 Issue: 2
Author(s): Jonathan Bain, Douglas R. Oyler, Susan S. Smyth and Tracy E. Macaulay
Affiliation:
Keywords: Venous thrombolism, pulmonary embolism, heparin, warfarin, EKOS, factor Xa inhibitors, direct thrombin inhibitors.
Abstract: Venous thrombosis is a common medical disorder affecting nearly one million Americans each year. This review will focus primarily on the formation of venous thrombosis as well as current and future treatment options. While the full pathophysiology of venous thrombosis is not known, recent evidence points to a role for von Willebrand Factor, platelets, and neutrophils in thrombus formation. Many laboratory and imaging tests may be used for the diagnosis of venous thrombosis (VTE), but risk factor identification and clinical examination should not be overlooked as they are vital in assuring accurate treatment and patient identification. Historically heparin followed by a vitamin K antagonist has been the standard of care for treatment of VTE, but increasing data involving factor Xa inhibitors and direct thrombin inhibitors may mean a shift in first-line therapy in the very near future. Invasive therapies such as catheter-directed thrombolysis have also shown promise in the treatment of venous thrombosis and will likely see increased use in the future.
Export Options
About this article
Cite this article as:
Bain Jonathan, Oyler R. Douglas, Smyth S. Susan and Macaulay E. Tracy, Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism, Current Drug Targets 2014; 15 (2) . https://dx.doi.org/10.2174/13894501113146660226
DOI https://dx.doi.org/10.2174/13894501113146660226 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer
Treatment
Current Bioactive Compounds Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options
Current Respiratory Medicine Reviews Radiolabeled Oligonucleotides for Antisense Imaging
Current Organic Synthesis The Pathogenesis of Susceptibility to Acute Kidney Injury in the Elderly
Current Aging Science Aetiology, Diagnosis and Treatment of Hydrops Foetalis
Current Pediatric Reviews Hypotensive Peptides from Snake Venoms: Structure, Function and Mechanism
Current Topics in Medicinal Chemistry Vitamin D: A Regulator of Metabolism and Inflammation
Current Nutrition & Food Science Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare
Reviews on Recent Clinical Trials Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry Aldose Reductase: A Novel Target for Cardioprotective Interventions
Current Drug Targets Hematopoietic Progenitor and Stem Cells Circulate by Surfing on Intracellular Ca2+ Waves: A Novel Target for Cell-based Therapy and Anti-cancer Treatment?
Current Signal Transduction Therapy Utility of γH2AX as a Molecular Marker of DNA Double-Strand Breaks in Nuclear Medicine: Applications to Radionuclide Therapy Employing Auger Electron-Emitting Isotopes
Current Radiopharmaceuticals The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) The Role of Minocycline in Ischemia-Reperfusion Injury: A Comprehensive Review of an Old Drug with New Implications
Recent Patents on Cardiovascular Drug Discovery NADPH Oxidases in the Heart
Current Cardiology Reviews Congestive Heart Failure: Pharmacological Agents and the Potential of BType Natriuretic Peptide
Current Medicinal Chemistry Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology